Revance Therapeutics Inc. (RVNC)
NASDAQ (NMS) NASDAQ (NMS) Primary 
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Revance Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Revance Therapeutics, Inc. Class Action: Levi & Korsinsky Reminds Revance Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of March 4, 2025 - RVNC
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
Investors in Revance Therapeutics, Inc. Should Contact Levi & Korsinsky Before March 4, 2025 to Discuss Your Rights - RVNC
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Revance Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - RVNC
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Class Action Filed Against Revance Therapeutics, Inc. (RVNC) Seeking Recovery for Investors - Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / If you suffered a loss on your Revance Therapeutics, Inc. (NASDAQ:RVNC) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: Click Here or contact Joseph E. Levi, Esq.
RVNC SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Revance Therapeutics, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
NEW YORK, NY / ACCESSWIRE / January 6, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or "the Company") (NASDAQ:RVNC) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period").
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Revance Therapeutics, Inc. and Certain Officers -RVNC
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC) and certain officers. The class action, filed in the United States District Court for the Middle District of Tennessee, and docketed under 25-cv- 00018 is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Revance securities between February 29, 2024 and December 6, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Shareholders that lost money on Revance Therapeutics, Inc.(RVNC) should contact Levi & Korsinsky about Securities Fraud Investigation - RVNC
NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Revance Therapeutics, Inc. ("Revance Therapeutics, Inc.") (NASDAQ:RVNC) concerning possible violations of federal securities laws. On September 23, 2024, Revance disclosed in a filing with the U.S. Securities and Exchange Commission that it "received a notice to remedy alleged material breaches, including breaches of the maximum levels of buffer stock and required efforts to promote and sell Teoxane products, under the Company's exclusive distribution agreement with Teoxane SA".
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Revance Therapeutics, Inc. - RVNC
NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ:RVNC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Revance Stock - Investors of Revance Therapeutics Inc. Encouraged to Contact Kehoe Law Firm, P.C. - RVNC
PHILADELPHIA, PA / ACCESSWIRE / November 8, 2024 / Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of Revance Therapeutics Inc. ("Revance" or the "Company") (NASDAQ:RVNC).
